{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-004930","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.114037+00:00","generated_at":"2026-06-17T10:38:45.329760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mustang Bio reports FY2022 net loss $77.5M; MB-106 shows 96% ORR, 75% CR","bullets":["Cash and equivalents $76.7M at Dec 31, 2022, down from $110.6M year-over-year.","Net loss $77.5M ($0.75/share) vs $66.4M ($0.76/share) in 2021; R&D expenses rose to $62.5M.","MB-106 CAR T therapy achieved 96% ORR and 75% CR in hematologic malignancies; FDA Orphan Drug Designation for Waldenstrom macroglobulinemia.","Completed $75M debt financing with Runway Growth Capital; $30M funded at close, $45M milestone-based.","Plans to treat first pivotal Phase 2 WM patient in Q1 2024; additional data expected in Q2 and Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-004930","json":"https://secwatch.observer/filing/0001558370-23-004930.json","markdown":"https://secwatch.observer/filing/0001558370-23-004930.md","text":"https://secwatch.observer/filing/0001558370-23-004930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/0001558370-23-004930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/tmb-20230329x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:38:45.329760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d6de05610c3f47e25c6f66aed51651c9608019f","claim":"MUSTANG BIO, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders was $77.5 million, or $0.75 per share, for the year ended December 31, 2022, EPS $0.75 per share.","evidence_excerpt":"Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/0001558370-23-004930-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"Net loss attributable to common stockholders was $77.5 million, or $0.75 per share, for the year ended December 31, 2022"},{"label":"EPS","value":"$0.75 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}